GLUE
Price
$4.22
Change
+$0.37 (+9.61%)
Updated
May 8 closing price
Capitalization
236.81M
90 days until earnings call
LYEL
Price
$0.42
Change
-$0.00 (-0.00%)
Updated
May 8, 04:59 PM (EDT)
Capitalization
124.34M
5 days until earnings call
Ad is loading...

GLUE vs LYEL

Header iconGLUE vs LYEL Comparison
Open Charts GLUE vs LYELBanner chart's image
Monte Rosa Therapeutics
Price$4.22
Change+$0.37 (+9.61%)
Volume$671.53K
Capitalization236.81M
Lyell Immunopharma
Price$0.42
Change-$0.00 (-0.00%)
Volume$13.03K
Capitalization124.34M
GLUE vs LYEL Comparison Chart
Loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GLUE vs. LYEL commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GLUE is a Buy and LYEL is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (GLUE: $4.22 vs. LYEL: $0.43)
Brand notoriety: GLUE and LYEL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: GLUE: 88% vs. LYEL: 70%
Market capitalization -- GLUE: $236.81M vs. LYEL: $124.34M
GLUE [@Biotechnology] is valued at $236.81M. LYEL’s [@Biotechnology] market capitalization is $124.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.75B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GLUE’s FA Score shows that 1 FA rating(s) are green whileLYEL’s FA Score has 0 green FA rating(s).

  • GLUE’s FA Score: 1 green, 4 red.
  • LYEL’s FA Score: 0 green, 5 red.
According to our system of comparison, GLUE is a better buy in the long-term than LYEL.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GLUE’s TA Score shows that 4 TA indicator(s) are bullish while LYEL’s TA Score has 3 bullish TA indicator(s).

  • GLUE’s TA Score: 4 bullish, 4 bearish.
  • LYEL’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, both GLUE and LYEL are a good buy in the short-term.

Price Growth

GLUE (@Biotechnology) experienced а -13.88% price change this week, while LYEL (@Biotechnology) price change was -8.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.66%. For the same industry, the average monthly price growth was +15.23%, and the average quarterly price growth was -12.40%.

Reported Earning Dates

GLUE is expected to report earnings on Aug 07, 2025.

LYEL is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (-3.66% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GLUE($237M) has a higher market cap than LYEL($124M). LYEL YTD gains are higher at: -34.219 vs. GLUE (-39.193). GLUE has higher annual earnings (EBITDA): -121.07M vs. LYEL (-200.64M). LYEL has more cash in the bank: 371M vs. GLUE (242M). GLUE has less debt than LYEL: GLUE (43.7M) vs LYEL (59M). GLUE has higher revenues than LYEL: GLUE (15M) vs LYEL (61K).
GLUELYELGLUE / LYEL
Capitalization237M124M191%
EBITDA-121.07M-200.64M60%
Gain YTD-39.193-34.219115%
P/E RatioN/AN/A-
Revenue15M61K24,590%
Total Cash242M371M65%
Total Debt43.7M59M74%
TECHNICAL ANALYSIS
Technical Analysis
GLUELYEL
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 2 days ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 16 days ago
88%
Bullish Trend 16 days ago
83%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGAVX14.07N/A
N/A
ClearBridge Global Infrastructure Inc A
VCFVX11.08N/A
N/A
VALIC Company I International Value
SSGVX127.06N/A
N/A
State Street Glb All Cap Eq ex-US Idx
PMAPX20.50N/A
N/A
Principal MidCap S&P 400 Index R6
SSAQX68.19N/A
N/A
State Street US Core Equity Fund

GLUE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with ATXS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
+9.61%
ATXS - GLUE
43%
Loosely correlated
-0.45%
IMNM - GLUE
42%
Loosely correlated
+3.77%
CRSP - GLUE
41%
Loosely correlated
+5.52%
RXRX - GLUE
40%
Loosely correlated
+4.77%
BEAM - GLUE
40%
Loosely correlated
+6.32%
More

LYEL and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYEL has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if LYEL jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYEL
1D Price
Change %
LYEL100%
+1.27%
VCYT - LYEL
46%
Loosely correlated
+0.92%
PRME - LYEL
45%
Loosely correlated
+6.77%
CRBU - LYEL
42%
Loosely correlated
+0.76%
RCKT - LYEL
42%
Loosely correlated
+6.18%
NTLA - LYEL
42%
Loosely correlated
+0.55%
More